CA1242974A - Parenteral nutrition with medium and long chain triglycerides - Google Patents
Parenteral nutrition with medium and long chain triglyceridesInfo
- Publication number
- CA1242974A CA1242974A CA000471737A CA471737A CA1242974A CA 1242974 A CA1242974 A CA 1242974A CA 000471737 A CA000471737 A CA 000471737A CA 471737 A CA471737 A CA 471737A CA 1242974 A CA1242974 A CA 1242974A
- Authority
- CA
- Canada
- Prior art keywords
- composition
- mcts
- emulsion
- lcts
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003626 triacylglycerols Chemical class 0.000 title abstract description 6
- 235000016236 parenteral nutrition Nutrition 0.000 title description 5
- 239000000839 emulsion Substances 0.000 claims abstract description 61
- 150000001413 amino acids Chemical class 0.000 claims abstract description 28
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 34
- 150000002632 lipids Chemical class 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- 150000005693 branched-chain amino acids Chemical group 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical group CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 claims 1
- JVQYSWDUAOAHFM-UHFFFAOYSA-N 3-methyl-2-oxovaleric acid Chemical compound CCC(C)C(=O)C(O)=O JVQYSWDUAOAHFM-UHFFFAOYSA-N 0.000 claims 1
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 31
- 235000016709 nutrition Nutrition 0.000 abstract description 10
- 230000035764 nutrition Effects 0.000 abstract description 8
- 239000003792 electrolyte Substances 0.000 abstract description 7
- 235000013343 vitamin Nutrition 0.000 abstract description 7
- 239000011782 vitamin Substances 0.000 abstract description 7
- 229940088594 vitamin Drugs 0.000 abstract description 7
- 229930003231 vitamin Natural products 0.000 abstract description 7
- 235000014633 carbohydrates Nutrition 0.000 abstract description 6
- 229940077731 carbohydrate nutrients Drugs 0.000 abstract description 5
- 239000002960 lipid emulsion Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 229940037395 electrolytes Drugs 0.000 abstract description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 25
- 241000700159 Rattus Species 0.000 description 22
- 150000004668 long chain fatty acids Chemical class 0.000 description 22
- 239000003921 oil Substances 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 19
- 230000037396 body weight Effects 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 229960001031 glucose Drugs 0.000 description 16
- 239000008121 dextrose Substances 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 9
- 208000019423 liver disease Diseases 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000004045 soybean oil emulsion Substances 0.000 description 9
- 239000004474 valine Substances 0.000 description 9
- 229960004295 valine Drugs 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229960003136 leucine Drugs 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 229960000310 isoleucine Drugs 0.000 description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 235000021476 total parenteral nutrition Nutrition 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 102000007562 Serum Albumin Human genes 0.000 description 5
- 108010071390 Serum Albumin Proteins 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 208000013223 septicemia Diseases 0.000 description 5
- 239000011573 trace mineral Substances 0.000 description 5
- 235000013619 trace mineral Nutrition 0.000 description 5
- BDBMLMBYCXNVMC-UHFFFAOYSA-O 4-[(2e)-2-[(2e,4e,6z)-7-[1,1-dimethyl-3-(4-sulfobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS(O)(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C BDBMLMBYCXNVMC-UHFFFAOYSA-O 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 102000003929 Transaminases Human genes 0.000 description 4
- 108090000340 Transaminases Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000019577 caloric intake Nutrition 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 208000027700 hepatic dysfunction Diseases 0.000 description 4
- 229960004657 indocyanine green Drugs 0.000 description 4
- 125000000468 ketone group Chemical group 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 230000003901 portacaval anastomosis Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009919 sequestration Effects 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 238000010911 splenectomy Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 208000031729 Bacteremia Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- -1 C12 fatty acids Chemical class 0.000 description 2
- 206010012225 Delirium tremens Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 206010056091 Varices oesophageal Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000024170 esophageal varices Diseases 0.000 description 2
- 201000010120 esophageal varix Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 210000001321 subclavian vein Anatomy 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003547 Asterixis Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000022563 Rema Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000010165 Tyrosinosis Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000003910 liver physiology Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000021076 total caloric intake Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT
Medium chain triglyceride containing lipid emulsions for the nutrition of liver diseased or septicemic patients are improved by the inclusion in the emulsions of long chain triglycerides.
The emulsions may also contain amino acids in proportions desirable for the nutrition of liver diseased patients, as well as carbohydrates, drugs, vitamins and electrolytes.
Medium chain triglyceride containing lipid emulsions for the nutrition of liver diseased or septicemic patients are improved by the inclusion in the emulsions of long chain triglycerides.
The emulsions may also contain amino acids in proportions desirable for the nutrition of liver diseased patients, as well as carbohydrates, drugs, vitamins and electrolytes.
Description
2~4 PARENTERAL NUTRITION WITH MEDIUM AND LONG CHAIN TRIGLYCERIDES
Background This relates to total parenteral nutrition of patients with liver disease or septicemia. It is particularly concerned with providing such nutrition via lipid emulsions.
Lipid emulsions for parenteral nutrition are available commercially or can be manufactured in accordance with known processes. Generally, such emulsions have been made using the triglycerides of long chain fatty acids (LCTs). LCTs are obtained conventionally from soybean or safflower oil. Long chain fatty acids are fatty acids having 14 or more carbon atoms, usually 16 or 18 carbon atoms.
More recently, lipid emulsions which contain triglycerides of medium chain fatty acids (MCTs) have become available~ MCTs are triglyceride esters of fatty acids which contain a preponderance of C8 and C10 fatty acids (caprylic and capric acid, respectively). Emulsions of this type are disclosed in European Patent Application 0071995 and Eckart et al., "J. Parenteral and Enteral Nutrition"
4(4):360-366 (1980). The above cited European Patent Application discloses an isotonic LCT/MCT emulsion for parenteral use, which contains a fat content of 3 to 30%, an LCT/MCT ratio between 4/1 and 1/4, a physiologically unobjectionable polyhydric alcohol and egg phosphatide as emulsifier.
,.~
Early studies involving enteral administration of MCT
emulsions to animals and man indicated that MCTs are handled by a physiological pathway other than the one known for LCTs.
In-depth studies revealed that MCTs are hydrolyzed to free fatty acids in the intestinal lumen at a rate five times faster than the hydrolysis rate for LCTs. Further, these MCT-derived fatty acids are absorbed by the intestinal cell at a rate twice the absorption rate of LCT-derived fatty acids. The most striking difference between MCT and LCT was shown to be the mechanism of transport to sites of utilization and, as a result, their predominant mode of utilization. MCT-derived fatty acids pass through the intestinal epithelial cell without reesterification to MCT. They then enter the portal vein, bind to albumin~ and are transported in this bound form in the bloodstream.
LCT-derived fatty acids, on the other hand, after absorption are reesterified in intestinal cells to form LCT and packaged with protein and phospholipids to form lipid particles tchylomicrons) that enter the lymph system and, later, the circulatory system for distribution to the tissues of utilization.
In comparison to LCTs, MCTs are much more readily utilized for caloric energy, but are less effectively incorporated into tissue lipids. MCTs, when administered orally, are believed to be metabolized primarily in the liver, while LCTs are metabolized throughout the body (Scheig, R. In: Medium Chain Triglycerides, J.R. Senior, Ed. pp 39-49 [1968]).
Liver disease as this term is used herein means a primary or secondary disorder of the liver parenchyma that results ~n reduced hepatic function. The etiologw of the disease may include but not be limited to any one of the following common disorders: Alcoholic cirrhosis, acute hepatocellular damage secondary to drug abuse or poisoning, genetic deficlencies such as tyrosinosis, trauma to the liver, hepatitis, primary biliary cirrhosis, liver abscess, Budd-Chiari syndrome, Wilson's disease, or primary or secondary liver neoplasms. Clinically, ~2~ Z~
hepatic dysfunction is diagnosed by increases in liver function tests such as serum glutamate-oxaloacetate transaminase, serum g1utamate-pyruvate transaminase and bilirubin, reductions in indocyanin green or bromosulphopthalein clearance, tissue biopsy, and/or neurological manifestations such as encephalopathy. Liver disease as defined herein excludes the subcl1nically mild and reversible hepatic dysfunction induced by parenteral nutrition (Eckart et al. Ibid).
Patients with septicemia include patients having subclinical septicemia or susceptibility to septicemia. Patients in this group include patients recuperating from abdominal surgery, patients with respiratory diseases and those with active infections such as abcesses or infected wounds.
Intravenous calorie intake in liver diseased patients is hampered by chronic carbohydrate and fluid intolerance. In addition, current LCT emulsions, although calorically dense, are contraindicated in liver disease because liver dysfunction is frequently associated with an impaired ability to metabolize LCT. A need exists for an intravenous calorie source for liver diseased patients that does not exhibit the disadvantages of available calorie sources.
MCTs have been included in oral formulations for the nutrition of stressed (including liver diseased~ patients. An example is the Travasorb~ Hepatic formulation sold by Travenol Laboratories, Inc. The doses of MCT to be delivered with such formulations have been low, however, on the order of about 0.2 mg MCT/Kg body weight (BW)/min. when following the instructions for use. MCTs are added to these nutrient formulations because they are believed necessary to circumvent the maladsorption of LCTs that accompanies deficient bile secretion by diseased livers. However, the low doses were believed mandated by the prevalent belief in the art that MCTs are harmful to liver diseased patients. See, for example, N. Greenberger et al.
~2~
"Ann. Intern. Med." _(4):727-734 (1967), who state that "it will be important to withhold MCT therapy from patients with decompensated cirrhosis until more is known about the effects of MCT therapy on such patients." (Id at p. 732). In part, this contraindication is based on the role of the liver as the primary s1te of medium chain fatty acid metabolism. The dysfunctional liver might not be expected to metabolize these fatty acids at a rate sufficient to avoid the observed effects of excess fatty acids in the blood: Somnolence, vomiting and even death. In addition, the narcotic effect of MCTs could be expected to exacerbate any tendency in liver diseased patients towards encephalopathy. Thus, MCTs have not been considered appropriate for providing a substantial percentage of the calorie needs of liver diseased patients.
We now have discovered that MCTs can be parenterally administered to recipients with liver disease or septicemia, and in dosages heretofore believed to be potentially hazardous, without toxic side effects. We have found that MCTs can supply nutritionally adequate calories to such patients without resulting in the liver fatty deposits or the reductions in the efficacy of the reticuloendothelial sys~em (RES) noted when supplying LCTs as a significant calorie source.
Summary The improvement herein comprises parenterally administering a composition comprising MCTs to a liver diseased patient or a patient with septicimia. It further comprises administering greater than about 0.35 mg MCTs/Kg BW/min. to such patients, preferably about from 0.5 to 2 mg MCTs/Kg BW/min., and selecting a weight proportion of MCTs to LCTs no greater than about 3 to l.
The improvement herein also comprises compositions including (1) a composition comprising (a)lipids wherein about -~ 5 ~4Z9~
from 25% to 75% by weight of the lipids are MOTs and the remainder are LCTs and (b)the branched chain amino acids, valine, leucine and/or isoleucine or the keto analogues of valine, leucine and/or valine.
(2) a compos~tion comprising MCTs and at least one branched chain amino acid, or preferably an amino acid mixture in which greater than about 35% of the mole weight of amino acids are valine, isoleucine and/or leucine or the keto analogues of valine, isoleucine and/or leucine.
Other aspects o~ this invention are as follows A sterile composition comprising an emulsion of MCTs and LCTs in an aqueous solution containing at least one branched chain amino acid or branched chain amino acid keto analogue.
A sterile emulsion com~rising, in relative weight proportion (a) MCTs, about ~rom 2.5 to 187;
(b) branched chain amino acids, about from 12.25 to 105; and - (c) LCTs, about ~rom 7.8 to 187.
Detailed Description The MCTs to be used herein will be C6, C8, C1O and/or C12 mixtures in proportions ranging in weight percent about from 0% to 3%, 50% to 100%, 50% to 100%, and OX to 3%, respectively. Usually only C8 and C10 fatty acids will be present, ~n ratios of about from 1:3 to 3:1. Preferably, the proportions C6, C8, C10 and C12 fatty acids will be < 2%, 65-80%, 20-35%, and < 2%. The MCT compositions can contain free fatty acids at up to about 0.005/mEq/g (USP), w~ll have a saponification value of about from 325-365 (USP) and an iodine value (USP Method II) of up to about 1.0 gI2/lOOg.
Color (Lovibond, AOCS Cc 13h.45) is preferab1y 1.0 R.
Unsaponifiable matter (USP), hydroxyl value ~USP), and heavy metals (USP Method II) should be less than about 1.0%, 10.0 and 10 ppm, respectively. The refractive index (USP) and specific gravity (USP) range from about 1.440 to 1.460 and 0.920 to 5a ~ z4Zg74 0.960, respec~ively. These specificat~ons are no~ crltlcal.
MCT oils of this ~ype are co~mercially available as lauric oils from coconut oil. The exact specifications, including the relative proportions of C6 to C12 medium chain fatty aclds, will vary somewhat since the MCTs are obtained from natural sources.
~2a. 2~74 --6~
The MCTs are used alone or incorporated with minor proportions of LCTs into the oil phase of an oil-in-aqueous emulsion. The proportion of MCTs to LCTS is preferably no more than about 3:1 hy weight. However, emulsions containing MCTs as the sole lipid source are suitable for use at physiologic nonprotein calorie intakes for the nutrition of liver diseased patients. Animals having surgically induced liver disease (disclosed in Example 5 below) have shown no tendency towards somnolence or overt encephalopathic symptoms upon administration of MCTs at substantial proportions of normal, physiologic nonprotein calorie intakes. MCT dosages of up to about 4mg MCTs/Kg/hr can be administered on a continuous basis, although the physician will need to tailor the maximum dose to the capabilities of the patient and be observant for toxicity symptoms such as vomiting and lethargy.
Studies with normal animals have disclosed that MCT toxicity can be ameliorated by supplying a proportion of non-protein calories as LCTs. A given hyperphysiological dose of MCTs may result in MCT toxicity symptoms, but the same dose accompanied by an approximately equal or minor proportion of LCTs will not produce the symptoms. Thus in the case of liver patients who exhibit various degrees of compromised MCT metabolic capacity, it is preferred that the MCT emulsions contain a proportion of LCTs, i.e., about from 15% to 50% by weight of the total lipids.
The MCT-containing emulsions may contain other substances besides LCTs~ These include surfactants such as egg or soya phospholipid, tonicity adjusting agents such as glycerol, carbohydrate nutrients such as dextrose, and electrolytes, amino acids, vitamins and trace minerals. The concentration by weight of the oil in the emulsion is about ~rom 5~ to 20%, with 20%
be~ng preferred.
The amino acid compositions used in the anueous phase of the emulsions for use with liver diseased patients preferably will have one or more of the following characteristics:
12a 2974 ~a) The total mole percent of the am;no acids serine, glycine, threonine, tryptophan, glutamine and histidine will range about from 8% to 16g;
(b) The total mole proportion of valine, leucine and isoleucine, (or the~r keto analoguesC~ -ketoisovaler~c, keto~socaproic and a -keto-g -methyl valeric asid, respect~vely) to the other amino acids w111 be greater than about 35%, preferably about 40% to 60% and ~ore optimally about 50%; and/or (c) A reduced proportion of sulfur-containing amino ac1ds, e.g. meth~onlne, when compared to standard formulations based on proteins such as egg white.
The amino acid composit~ons optimally will include essential and nonessential amino acids, in the latter group especially arginine and histidine. These last two amino acids are known to be desirable in the nutrit~on of liver diseased patients. A
representative amino acid composition is disclosed in PCT
International Application published as WO 83/00085. Other representative compositions that have been urged to be useful in the nutrit~on of liver diseased patients are disclosed in U.S.
patents 3,950~529; 4,100,293, 3,832,465; and 4,259,353; and U.K.
patent 2,037,161A. The amino acids are desirably supplied in the crystalline form rather than as protein hydrolysates. The amount o~ am~no acids included in the emulsions will be sufficient to ma~ntain patients' nitrogen requtrements at the planned rate of infusion of MCT and/or LCT calories.
The lipid partlcles ~n the emuls~on will have a diameter of less than about 0.75 ~m and preferably less than abou~ 0.5~m.
The emulslons will be ster~le and ord~nar~ly are packaged fn glass conta~ners. They can be made by known methods. For example see U.S. patent 3,169,094;
The contribution of lipid to total nonprotein calories in the emulsions herein ordinarily will range about from 20% to ~L2~97~
80%. Thus ~he MCTs in the emulsion will make up about from 5%
to 60% of the total nonprotein calories in the emulsions, preferably about from 15% to 60%. For example in a 70 Kg man receiving ~0 kcals/Kg BW/day, MCT dosage may vary about from 0.35 mg/Kg BW/min. to 2.05 mg/Kg BW/min., preferably about from 0.4 mg/Kg BW/min. to 1.00 mg/Kg BW/min. and optimally about from 0.5 to .75 mg/Kg BW/min. The remaining nonprotein calories are carbohydrates or a mixture of LCTs and carbohydrates.
A convenient method for preparing and administering the emulsion herein is for the hospital or user pharmacy to sterile mix the emulsion components using commercially available equipment. The MCT and LCT emulsions are mixed with sterile aqueous solutions of other desirable additives: Amino acids in proportions suitable for disease nutrition, vitamins, carbohydrates such as dextrose, electrolytes such as potassium and sodium chloride drugs, and trace minerals such as zinc ions. The resulting product is a sterile, emulsion of MCTs and LCTs, in an aqueous solution containing amino acids in proportions characterized above, carbohydrate and, optionally, drugs, trace minerals and vitamins. Alternatively, and less preferably, the MCTs and LCTs can be mixed as oils, then emulsified and combined with the other additives noted above.
Drugs which have heretofore been conventionally administered to liver disease patients (cymeditine or steroids) or septic~mia patients (antibiotics) may be included in the emulsion.
The emulsions herein are packaged and stored in hermetically sealed containers for long or short term storage. The additives to be included in the emulsions will depend upon how long the emulsions are to be stored. Long term storage is acceptable for emulsions with aqueous phases containing sugar, the amino acids and some electrolytes. Dextrose should not be included in emulsions prepared for long term storage. They are administered continuously or discontinuously by infusion into the subclavian vein as is the conventional practice in total parenteral nutrition. When LCT
7~
and MCT emulsions are combined in pharmacies or are mixed with other solutions for short-term storage as discussed above they may be stored in flexible containers now available commercially for temporary storage of LCT emulsion admixtures.
The following examples are merely illustrative and are not to be considered limiting with respect to the claims.
Ordinarily the emulsions are stored in glass containers.
In a suitable mixing vessel, 2.0 kg of MCT oil consisting of approximately 75% octanoic acid and 25% decanoic acid, 120 g of purified egg phospholipids, 225 g of glycerol, USP, and a suitable quantity of water for injection, USP, are mixed to produce a coarse emulsion. This emulsion is then homogenized repeatedly at high pressure to produce an emulsion of mean particle diameter of less than 0-75 t~m. During the process, the pH of the emulsion is adjusted to a physiological range with sodium hydroxide. The final volume is adjusted, if necessary, with water for injection, USP, to 10 L and the emulsion filtered into glass containers and heat sterilized by the normal procedure.
To a 2 L plastic bag suitable for intravenous admixtures (Travamulsion~ container) is added 385 mls of a 10% crystalline amtno acid solution (Travasol~ 10%; Travenol Laboratories, Inc.), 535 mls of 4% isomolar branched amino acid (leucine, isoleucine, and valine) solution, 430 mls of 70% hydrous dextrose, 63 mls of 20% soybean oil emulsion (Travamulsion 10%; Travenol Laboratories, Inc.), 217 mls of a 20% MCT oil emulsion of Example 1 and 90 mls of a solution containing ~z~z~
appropr;ate electrolytes, trace minerals and vitamins. The solution is mixed by hand and is connected to an infusion pump suitable for administration into a patient. The solution contains 60 gms of amino acids and a total of 1800 kcals. 65%
of the nonprotein calories are hydrous dextrose and 35% of the nonprotein calories are lip;d.
The solution may be administered to a hospitalized patient over 24 hours at a constant rate of 72 mls/hr.
In a suitable mixing vessel, approximately 1.5 kg of MCT oil and 0.5 kg of soybean oil, 120 g of purified egg phospholipids, 225 9 of glycerol, USP, and a suitable quantity of water for injection, USP, are mixed to produce a coarse emulsion. This emulsion is then homogenized repeatedly at high pressure to produce an emulsion of mean particle diameter of less than 0 75 t~m. During the process the pH of the emulsion is adjusted to a ph~siological range with sodium hydroxide. The final volume is adjusted, if necessary with water for injection, USP, to 10 L and the emulsion filtered into glass containers and heat sterilized by the normal procedure.
To a 2 L container suitable for intravenous infusions of admixtures (Travamulsion~ container) is added 385 mls of a crystalline amino acid solution (Travasol~ 10%; Travenol Laboratories, Inc.), ~35 mls of 4% isomolar branched chain amino 2~Z~
acid (leucine, isoleucine, and valine) solution, 430 mls of hydrous dextrose, 560 mls of 10% lipid emulsion comprised of 7~%
MCT oil and 25% soybean oil (Example 3) and 90 mls of a solution containing appropriate electrolytes, trace m;nerals and vitamins. The resulting solution is mixed by hand and is connected to an infusion pump suitable for administration into a patient. The solution contains 60 gms of amino acid and a total of 1800 kcals. 65% of the nonprotein calories are hydrous dextrose and 35% of the nonprotein calories are lipid in the form of a 75% ~CT oil emulsion and 25% soybean oll emulsion.
The solution may be administered to a hospitalized patient over a 24-hour period at a constant rate of 72 mls/hour.
EXAMPLE ~
Hepatic insufficiency was induced in previously healthy Sprague-Dawley CRl:CD rats by portacaval anastomosis. An end-to side portacaval anastomosis (shunt) was induced by a nonsuture method using Teflon tubing. For three weeks following surgery, the rats were returned to stainless steel cages and allowed ~o consume laboratory chow, ad libitum. After that period in time, 24 animals were fasted overnight and hepatic function assessed by both static and dynamic indices. Results were compared to 20 similar animals that received only a sham operation.
In 12 portacaval shunted rats and 10 sham operated rats, indocyanine green clearance~ an index of hepatocyte function, was evaluated.
Fifteen minutes following intravenous injection of ~ndocyanin2 green, both sham operated and portacaval shunted rats were killed and results are summarized in Table 1.
lZ4Zg~
TABLE 1 Portocaval Shunt (PCS) Effects on Body ~leight, Liver Weight, Indocyanine Green Clearance and Serum Albumin Concentrations - -Indocyanine Body Welght (g) Liver Green Serum Albumin Before After Weight (g) Retention(%) (g/dl) SHAM 274+8 351+15 8.9~0.6 9.0+3.3 3.05~0.04 PCS 277~23 301+35 6.2+0.4* 18.3+4.7*2.68+0.16*
*p n.o5 Hepatic dysfunction was clearly evident. Liver weight in portacaval shunted rats was 42% less than in sham operated animals (p 0.05) and serum albumin concentration (a liver synthesized protein) was also significantly reduced (p 0.05).
As a dynamic assessment of hepatocyte function, indocyanine green retention was almost twice as great (p 0.05) in portacaval shunted rats indicating reduced clearance.
In addition to these assessments, hepatic reticuloendothelial system function was evaluated in 12 additional portacaval shunted rats and 10 sham operated rats.
The blood concentration of live Pseudomonas aeruginosa P4 in portacaval shunted rats following an intravenous challenge of 5X108 cfu of bacteria was about ten times greater (one log) than the sham operated group (Table 2) (p 0.05). Although the capacity to clear bacteria was reduced in portacaval shunted rats, the capacity of the spleens to sequester Pseudomonas was markedly increased, indicating a compensatory role by that organ.
~24zg7 TABLE 2 Effect of PCS on Host Nonspecific Immunity and Organ Reticuloendothelial System Function Blood Bacteremia (log conc.) Organ Sequestration i%) O' 30' 60' Liver Spleen SHAM 74.5+0.3 3.0+0.3 35+2 6+1 PCS 75.4+0.2* 4.2+0.2* 38+2 12+1 _ *p 0.05 Therefore, the portacaval shunt model in the rat produced a hepatic ~nsufficiency model which mimics in many ways the clinical conditions seen in human liver disease.
Twenty-eight male Sprague-Dawley CRl:CD rats underwent portacaval anastomosis and splenectomy and were returned to their metabolic units for 3 weeks. Following the recovery period, the rats were randomized to receive total parenteral nutrition for four days. All of the diets delivered 300 kcals/Kg BW/day and 12.5 g amino acid/day except for the dextrose only group t"D only") which received only 300 dextrose kcals/Kg BW/day. One group of animals received all of the nonprotein calories as dextrose ~AA+D) whereas the remaining two groups received half of their nonprotein calories as lipid. One of the lipid groups received its fat calories as a soybean (LCT) oil emulsion (AA+D~L) while the rema~ning lipid group received one-half o~ the fat calories as the 20~ MCT oil emulsion of example 7 and the other half as a 20% soybean oil emulsion (AA+D+PM).
~"~a,2~37~
TABLE 3 Protein Responses to Various TPN Regimens in Portocaval Shunted Rats.
Serum Albumin Fractional Synthetic Rate(%/d) N Balance (g/dl~ Albumin Muscle (mg/4 days) M+D+PM 3.2+0.3*85~14 5.7+2.2 61+14 AA+D~5T 3.0+0.5 84+15 6.1+1.2 20+35 AA+D 2.6+0.3 68+5 5.9+1.0 71+32 D only 2.4+0.5 20+8* 5.6+2.8 -150+10*
*p 0.05 vs M+D
Results summarized in Table 3 demonstrated that portacaval shunted rats given the 5~:50 physical mixture ~PM) of MCT
emulsion and soybean oil emulsion had the highest serum level of albumin (a hepatic secretory protein), and serum albumin levels were lowest in animals given only glucose. In addition, liver histologw (following hemotoxylin and eosin staining~ sho~ed marked infiltration of glycogen in the hepatocytes from rats infused with dextrose regimens (AA+D and D only). In contrast, in rats given all of their nonprotein calories as a soybean oil emulsion and glucose (Group AA+D+LCT) increased lipid sequestration in the Kupffer cells was observed. Rats given nonprotein calories as glucose and the physical mix of soybean and MCT oil emulsion (AA+D~PM) had normal hepatic physiology.
The improved liver morphology and albumin concentration in the rats given the 50:50 physical mix of soybean oil emulsion and MCT oil emulsion support the conclusion that MCTs as a component of total parenteral nutrition are an effective energy source during hepatic dysfunction.
~2~ 2~7~
The effect of MCT emulsions on reticuloendothelial system function was investigated in 2~ additional portacaval shunted rats that had also undergone splenectomy. Seven weeks following portacaval anastomosis and splenectomy, all animals received diets that delivered 200 kcals/Kg BW/day and 8.3 9 amino acid/Kg BW/day. Lipid was given at 50% of the total nonprotein calorie intake as either a 10% soybean oll emulsion (AA+D+LCT) or a 10%
MCT oil emulsion (AA+D+MCn. To assess reticuloendothelial system function following these courses of total parenteral nutrition, a body weight-related dose of E. coli was administered intravenously.
TABLE 4 Effect of MCT AND LCT on Reticuloendothelial System Function in PCS Ra~s N Blood Organ Balance Bacteria (log conc) Sequestration (%) (mg/5d) O' 30' 60' Liver Lung SHAM + AA~D+LCT 117+15 74.2+0.4* 3.4+0.236.4+1.212.5+1.2 PCS + M+D+LCT 101+38 75.5+0.3 4.8+0.242.1+2.315.5+2.0 PCS + AA+D+M~T 105+18 74.5+001* 3.9+0.2* 55.7+4.5* 8.4+0.7*
*p 0.05 vs PCS +AA+D+LCT
No differences in nitrogen balance were observed (Table 4).
However, decreased bacterial clearance and liver uptake of E.
coli indicakive of hepatic reticuloendolthelial system blockade were seen 1n portacaval shunted and splenectomized rats given lipid calories as a soybean oil emulsion. Such results suggest that administration of LCT oil emulsions without MCTs may have adverse effects during hepatic insufficiency. In contrast, intravenous MCT emulsions support nitrogen balance equally well 9~
and may better support hepatic reticuloendothelial system function in order to improve sequestration of organisms in the liver during bacteremia.
This contemplated example demonstrates the use of an MCT
emulsion in providing parenteral nutrition to a liver diseased patient.
A 47-year-old ~hite male (62 K~) is admitted to the hospital because of delirium and hematemesis. The patient had a 25 year history of alcohol abuse and on a previous admission had biopsy proven alcoholic cirrhosis. Gastroscopy had demonstrated the presence of extensive esophageal varices.
Laboratory analysis of the patient confirmed the clinical diagnosis of variceal bleeding secondary to decompensated alcoholic cirrhosis. Total bilirubin was 7 mg/dl (normal less than 1 mg/dl); serum glutamate-oxalo acetate transaminase was 80 U/L (normal less than 15 U/L). Serum glutamate pyruvate transaminase was 155 U/L (normal less than 15 U/L) and serum gamma glutaryl transaminase was 180 U/L (normal less than 30 U/L). Hemoglobin was 7.5 g/l (normal = 1~-16 9/1).
Serum alburnin concentration was 1.9 g/dl (normal greater than 3.5 g/dl) and total protein 4.4 g/dl (normal greater than 6 g/dl) reflecting visceral protein attrition. Abnormalities in the serum amino acid pattern were also evident with L-tyrosine being 274 nmols/ml (normal 50-100 nmols/ml) and L-phenylalanine being 332 nmols/ml (normal 50-100 nmols/ml). The serum aromatic to branched chain amino acid ratio was 2.7~ with normal being less than 0.80.
The patient's mental condition varied from Grade II to Grade III coma and the patient had severe asterixis. During the first two days of admission, 2 gms of neomycin, twice daily, and 20 mls of 10% lactolose three times daily, were administered. Due ~24Z9~
to acute alcohol wi~hdrawal, the patient's clinical course was complicated by the presence of alcohol-induced delirium tremens.
Because of the patient's reduced visceral protein status, nutritional support was recommended. Oral intake was not recommended because of the decreased mental status and presence of delirium tremens. Use of nasogastric feeding tube was also contraindicated because of esophageal varices. The physicians recommended total intravenous nutrition and a subclavlan catheter was inserted into the superior vena cava.
Nutritional support for the patient was set at a total calorie intake of 30 kcals/Kg BW/day and protein (as amino acid equivalents) at l.Og/Kg BW/day. The amino acid source was a standard amino acid mixture (Travasol amino acids) supplemented with the branched chain amino acids, leucine, isoleucine, and valine so that the total branched chain proportion was 50% of the total amino acids by weight.
The remaining 26 kcals/Kg BW/day were administered as 65%
hydrous glucose and 35% as a physical mixture of 20% MCT oil emulsion and 20% soybean oil emulsion. 75% of the lipid calories were given as the medium chain triglyceride oil emulsion and 25% of the lipid calories as a soybean oil emulsion. Actual daily intake of the hydrous glucose was 3.5 mg/Kg/min, of the soybean oil emulsion was 0.174 mg/Kg/min and of the MCT oil emulsion, 0.585 mg/Kg/min. Electrolytes, trace minerals, and vitamins were adjusted daily to meet the established requirements of the patient.
The entire formula was admfnistered in a course of therapy commencing with 1720 ml of fluid continuously over a 24 hour period at a rate of 72 mls/hr through the subclavian vein catheter. The patient's condition was considered to have improved after treatment with the regimen of this Example.
Background This relates to total parenteral nutrition of patients with liver disease or septicemia. It is particularly concerned with providing such nutrition via lipid emulsions.
Lipid emulsions for parenteral nutrition are available commercially or can be manufactured in accordance with known processes. Generally, such emulsions have been made using the triglycerides of long chain fatty acids (LCTs). LCTs are obtained conventionally from soybean or safflower oil. Long chain fatty acids are fatty acids having 14 or more carbon atoms, usually 16 or 18 carbon atoms.
More recently, lipid emulsions which contain triglycerides of medium chain fatty acids (MCTs) have become available~ MCTs are triglyceride esters of fatty acids which contain a preponderance of C8 and C10 fatty acids (caprylic and capric acid, respectively). Emulsions of this type are disclosed in European Patent Application 0071995 and Eckart et al., "J. Parenteral and Enteral Nutrition"
4(4):360-366 (1980). The above cited European Patent Application discloses an isotonic LCT/MCT emulsion for parenteral use, which contains a fat content of 3 to 30%, an LCT/MCT ratio between 4/1 and 1/4, a physiologically unobjectionable polyhydric alcohol and egg phosphatide as emulsifier.
,.~
Early studies involving enteral administration of MCT
emulsions to animals and man indicated that MCTs are handled by a physiological pathway other than the one known for LCTs.
In-depth studies revealed that MCTs are hydrolyzed to free fatty acids in the intestinal lumen at a rate five times faster than the hydrolysis rate for LCTs. Further, these MCT-derived fatty acids are absorbed by the intestinal cell at a rate twice the absorption rate of LCT-derived fatty acids. The most striking difference between MCT and LCT was shown to be the mechanism of transport to sites of utilization and, as a result, their predominant mode of utilization. MCT-derived fatty acids pass through the intestinal epithelial cell without reesterification to MCT. They then enter the portal vein, bind to albumin~ and are transported in this bound form in the bloodstream.
LCT-derived fatty acids, on the other hand, after absorption are reesterified in intestinal cells to form LCT and packaged with protein and phospholipids to form lipid particles tchylomicrons) that enter the lymph system and, later, the circulatory system for distribution to the tissues of utilization.
In comparison to LCTs, MCTs are much more readily utilized for caloric energy, but are less effectively incorporated into tissue lipids. MCTs, when administered orally, are believed to be metabolized primarily in the liver, while LCTs are metabolized throughout the body (Scheig, R. In: Medium Chain Triglycerides, J.R. Senior, Ed. pp 39-49 [1968]).
Liver disease as this term is used herein means a primary or secondary disorder of the liver parenchyma that results ~n reduced hepatic function. The etiologw of the disease may include but not be limited to any one of the following common disorders: Alcoholic cirrhosis, acute hepatocellular damage secondary to drug abuse or poisoning, genetic deficlencies such as tyrosinosis, trauma to the liver, hepatitis, primary biliary cirrhosis, liver abscess, Budd-Chiari syndrome, Wilson's disease, or primary or secondary liver neoplasms. Clinically, ~2~ Z~
hepatic dysfunction is diagnosed by increases in liver function tests such as serum glutamate-oxaloacetate transaminase, serum g1utamate-pyruvate transaminase and bilirubin, reductions in indocyanin green or bromosulphopthalein clearance, tissue biopsy, and/or neurological manifestations such as encephalopathy. Liver disease as defined herein excludes the subcl1nically mild and reversible hepatic dysfunction induced by parenteral nutrition (Eckart et al. Ibid).
Patients with septicemia include patients having subclinical septicemia or susceptibility to septicemia. Patients in this group include patients recuperating from abdominal surgery, patients with respiratory diseases and those with active infections such as abcesses or infected wounds.
Intravenous calorie intake in liver diseased patients is hampered by chronic carbohydrate and fluid intolerance. In addition, current LCT emulsions, although calorically dense, are contraindicated in liver disease because liver dysfunction is frequently associated with an impaired ability to metabolize LCT. A need exists for an intravenous calorie source for liver diseased patients that does not exhibit the disadvantages of available calorie sources.
MCTs have been included in oral formulations for the nutrition of stressed (including liver diseased~ patients. An example is the Travasorb~ Hepatic formulation sold by Travenol Laboratories, Inc. The doses of MCT to be delivered with such formulations have been low, however, on the order of about 0.2 mg MCT/Kg body weight (BW)/min. when following the instructions for use. MCTs are added to these nutrient formulations because they are believed necessary to circumvent the maladsorption of LCTs that accompanies deficient bile secretion by diseased livers. However, the low doses were believed mandated by the prevalent belief in the art that MCTs are harmful to liver diseased patients. See, for example, N. Greenberger et al.
~2~
"Ann. Intern. Med." _(4):727-734 (1967), who state that "it will be important to withhold MCT therapy from patients with decompensated cirrhosis until more is known about the effects of MCT therapy on such patients." (Id at p. 732). In part, this contraindication is based on the role of the liver as the primary s1te of medium chain fatty acid metabolism. The dysfunctional liver might not be expected to metabolize these fatty acids at a rate sufficient to avoid the observed effects of excess fatty acids in the blood: Somnolence, vomiting and even death. In addition, the narcotic effect of MCTs could be expected to exacerbate any tendency in liver diseased patients towards encephalopathy. Thus, MCTs have not been considered appropriate for providing a substantial percentage of the calorie needs of liver diseased patients.
We now have discovered that MCTs can be parenterally administered to recipients with liver disease or septicemia, and in dosages heretofore believed to be potentially hazardous, without toxic side effects. We have found that MCTs can supply nutritionally adequate calories to such patients without resulting in the liver fatty deposits or the reductions in the efficacy of the reticuloendothelial sys~em (RES) noted when supplying LCTs as a significant calorie source.
Summary The improvement herein comprises parenterally administering a composition comprising MCTs to a liver diseased patient or a patient with septicimia. It further comprises administering greater than about 0.35 mg MCTs/Kg BW/min. to such patients, preferably about from 0.5 to 2 mg MCTs/Kg BW/min., and selecting a weight proportion of MCTs to LCTs no greater than about 3 to l.
The improvement herein also comprises compositions including (1) a composition comprising (a)lipids wherein about -~ 5 ~4Z9~
from 25% to 75% by weight of the lipids are MOTs and the remainder are LCTs and (b)the branched chain amino acids, valine, leucine and/or isoleucine or the keto analogues of valine, leucine and/or valine.
(2) a compos~tion comprising MCTs and at least one branched chain amino acid, or preferably an amino acid mixture in which greater than about 35% of the mole weight of amino acids are valine, isoleucine and/or leucine or the keto analogues of valine, isoleucine and/or leucine.
Other aspects o~ this invention are as follows A sterile composition comprising an emulsion of MCTs and LCTs in an aqueous solution containing at least one branched chain amino acid or branched chain amino acid keto analogue.
A sterile emulsion com~rising, in relative weight proportion (a) MCTs, about ~rom 2.5 to 187;
(b) branched chain amino acids, about from 12.25 to 105; and - (c) LCTs, about ~rom 7.8 to 187.
Detailed Description The MCTs to be used herein will be C6, C8, C1O and/or C12 mixtures in proportions ranging in weight percent about from 0% to 3%, 50% to 100%, 50% to 100%, and OX to 3%, respectively. Usually only C8 and C10 fatty acids will be present, ~n ratios of about from 1:3 to 3:1. Preferably, the proportions C6, C8, C10 and C12 fatty acids will be < 2%, 65-80%, 20-35%, and < 2%. The MCT compositions can contain free fatty acids at up to about 0.005/mEq/g (USP), w~ll have a saponification value of about from 325-365 (USP) and an iodine value (USP Method II) of up to about 1.0 gI2/lOOg.
Color (Lovibond, AOCS Cc 13h.45) is preferab1y 1.0 R.
Unsaponifiable matter (USP), hydroxyl value ~USP), and heavy metals (USP Method II) should be less than about 1.0%, 10.0 and 10 ppm, respectively. The refractive index (USP) and specific gravity (USP) range from about 1.440 to 1.460 and 0.920 to 5a ~ z4Zg74 0.960, respec~ively. These specificat~ons are no~ crltlcal.
MCT oils of this ~ype are co~mercially available as lauric oils from coconut oil. The exact specifications, including the relative proportions of C6 to C12 medium chain fatty aclds, will vary somewhat since the MCTs are obtained from natural sources.
~2a. 2~74 --6~
The MCTs are used alone or incorporated with minor proportions of LCTs into the oil phase of an oil-in-aqueous emulsion. The proportion of MCTs to LCTS is preferably no more than about 3:1 hy weight. However, emulsions containing MCTs as the sole lipid source are suitable for use at physiologic nonprotein calorie intakes for the nutrition of liver diseased patients. Animals having surgically induced liver disease (disclosed in Example 5 below) have shown no tendency towards somnolence or overt encephalopathic symptoms upon administration of MCTs at substantial proportions of normal, physiologic nonprotein calorie intakes. MCT dosages of up to about 4mg MCTs/Kg/hr can be administered on a continuous basis, although the physician will need to tailor the maximum dose to the capabilities of the patient and be observant for toxicity symptoms such as vomiting and lethargy.
Studies with normal animals have disclosed that MCT toxicity can be ameliorated by supplying a proportion of non-protein calories as LCTs. A given hyperphysiological dose of MCTs may result in MCT toxicity symptoms, but the same dose accompanied by an approximately equal or minor proportion of LCTs will not produce the symptoms. Thus in the case of liver patients who exhibit various degrees of compromised MCT metabolic capacity, it is preferred that the MCT emulsions contain a proportion of LCTs, i.e., about from 15% to 50% by weight of the total lipids.
The MCT-containing emulsions may contain other substances besides LCTs~ These include surfactants such as egg or soya phospholipid, tonicity adjusting agents such as glycerol, carbohydrate nutrients such as dextrose, and electrolytes, amino acids, vitamins and trace minerals. The concentration by weight of the oil in the emulsion is about ~rom 5~ to 20%, with 20%
be~ng preferred.
The amino acid compositions used in the anueous phase of the emulsions for use with liver diseased patients preferably will have one or more of the following characteristics:
12a 2974 ~a) The total mole percent of the am;no acids serine, glycine, threonine, tryptophan, glutamine and histidine will range about from 8% to 16g;
(b) The total mole proportion of valine, leucine and isoleucine, (or the~r keto analoguesC~ -ketoisovaler~c, keto~socaproic and a -keto-g -methyl valeric asid, respect~vely) to the other amino acids w111 be greater than about 35%, preferably about 40% to 60% and ~ore optimally about 50%; and/or (c) A reduced proportion of sulfur-containing amino ac1ds, e.g. meth~onlne, when compared to standard formulations based on proteins such as egg white.
The amino acid composit~ons optimally will include essential and nonessential amino acids, in the latter group especially arginine and histidine. These last two amino acids are known to be desirable in the nutrit~on of liver diseased patients. A
representative amino acid composition is disclosed in PCT
International Application published as WO 83/00085. Other representative compositions that have been urged to be useful in the nutrit~on of liver diseased patients are disclosed in U.S.
patents 3,950~529; 4,100,293, 3,832,465; and 4,259,353; and U.K.
patent 2,037,161A. The amino acids are desirably supplied in the crystalline form rather than as protein hydrolysates. The amount o~ am~no acids included in the emulsions will be sufficient to ma~ntain patients' nitrogen requtrements at the planned rate of infusion of MCT and/or LCT calories.
The lipid partlcles ~n the emuls~on will have a diameter of less than about 0.75 ~m and preferably less than abou~ 0.5~m.
The emulslons will be ster~le and ord~nar~ly are packaged fn glass conta~ners. They can be made by known methods. For example see U.S. patent 3,169,094;
The contribution of lipid to total nonprotein calories in the emulsions herein ordinarily will range about from 20% to ~L2~97~
80%. Thus ~he MCTs in the emulsion will make up about from 5%
to 60% of the total nonprotein calories in the emulsions, preferably about from 15% to 60%. For example in a 70 Kg man receiving ~0 kcals/Kg BW/day, MCT dosage may vary about from 0.35 mg/Kg BW/min. to 2.05 mg/Kg BW/min., preferably about from 0.4 mg/Kg BW/min. to 1.00 mg/Kg BW/min. and optimally about from 0.5 to .75 mg/Kg BW/min. The remaining nonprotein calories are carbohydrates or a mixture of LCTs and carbohydrates.
A convenient method for preparing and administering the emulsion herein is for the hospital or user pharmacy to sterile mix the emulsion components using commercially available equipment. The MCT and LCT emulsions are mixed with sterile aqueous solutions of other desirable additives: Amino acids in proportions suitable for disease nutrition, vitamins, carbohydrates such as dextrose, electrolytes such as potassium and sodium chloride drugs, and trace minerals such as zinc ions. The resulting product is a sterile, emulsion of MCTs and LCTs, in an aqueous solution containing amino acids in proportions characterized above, carbohydrate and, optionally, drugs, trace minerals and vitamins. Alternatively, and less preferably, the MCTs and LCTs can be mixed as oils, then emulsified and combined with the other additives noted above.
Drugs which have heretofore been conventionally administered to liver disease patients (cymeditine or steroids) or septic~mia patients (antibiotics) may be included in the emulsion.
The emulsions herein are packaged and stored in hermetically sealed containers for long or short term storage. The additives to be included in the emulsions will depend upon how long the emulsions are to be stored. Long term storage is acceptable for emulsions with aqueous phases containing sugar, the amino acids and some electrolytes. Dextrose should not be included in emulsions prepared for long term storage. They are administered continuously or discontinuously by infusion into the subclavian vein as is the conventional practice in total parenteral nutrition. When LCT
7~
and MCT emulsions are combined in pharmacies or are mixed with other solutions for short-term storage as discussed above they may be stored in flexible containers now available commercially for temporary storage of LCT emulsion admixtures.
The following examples are merely illustrative and are not to be considered limiting with respect to the claims.
Ordinarily the emulsions are stored in glass containers.
In a suitable mixing vessel, 2.0 kg of MCT oil consisting of approximately 75% octanoic acid and 25% decanoic acid, 120 g of purified egg phospholipids, 225 g of glycerol, USP, and a suitable quantity of water for injection, USP, are mixed to produce a coarse emulsion. This emulsion is then homogenized repeatedly at high pressure to produce an emulsion of mean particle diameter of less than 0-75 t~m. During the process, the pH of the emulsion is adjusted to a physiological range with sodium hydroxide. The final volume is adjusted, if necessary, with water for injection, USP, to 10 L and the emulsion filtered into glass containers and heat sterilized by the normal procedure.
To a 2 L plastic bag suitable for intravenous admixtures (Travamulsion~ container) is added 385 mls of a 10% crystalline amtno acid solution (Travasol~ 10%; Travenol Laboratories, Inc.), 535 mls of 4% isomolar branched amino acid (leucine, isoleucine, and valine) solution, 430 mls of 70% hydrous dextrose, 63 mls of 20% soybean oil emulsion (Travamulsion 10%; Travenol Laboratories, Inc.), 217 mls of a 20% MCT oil emulsion of Example 1 and 90 mls of a solution containing ~z~z~
appropr;ate electrolytes, trace minerals and vitamins. The solution is mixed by hand and is connected to an infusion pump suitable for administration into a patient. The solution contains 60 gms of amino acids and a total of 1800 kcals. 65%
of the nonprotein calories are hydrous dextrose and 35% of the nonprotein calories are lip;d.
The solution may be administered to a hospitalized patient over 24 hours at a constant rate of 72 mls/hr.
In a suitable mixing vessel, approximately 1.5 kg of MCT oil and 0.5 kg of soybean oil, 120 g of purified egg phospholipids, 225 9 of glycerol, USP, and a suitable quantity of water for injection, USP, are mixed to produce a coarse emulsion. This emulsion is then homogenized repeatedly at high pressure to produce an emulsion of mean particle diameter of less than 0 75 t~m. During the process the pH of the emulsion is adjusted to a ph~siological range with sodium hydroxide. The final volume is adjusted, if necessary with water for injection, USP, to 10 L and the emulsion filtered into glass containers and heat sterilized by the normal procedure.
To a 2 L container suitable for intravenous infusions of admixtures (Travamulsion~ container) is added 385 mls of a crystalline amino acid solution (Travasol~ 10%; Travenol Laboratories, Inc.), ~35 mls of 4% isomolar branched chain amino 2~Z~
acid (leucine, isoleucine, and valine) solution, 430 mls of hydrous dextrose, 560 mls of 10% lipid emulsion comprised of 7~%
MCT oil and 25% soybean oil (Example 3) and 90 mls of a solution containing appropriate electrolytes, trace m;nerals and vitamins. The resulting solution is mixed by hand and is connected to an infusion pump suitable for administration into a patient. The solution contains 60 gms of amino acid and a total of 1800 kcals. 65% of the nonprotein calories are hydrous dextrose and 35% of the nonprotein calories are lipid in the form of a 75% ~CT oil emulsion and 25% soybean oll emulsion.
The solution may be administered to a hospitalized patient over a 24-hour period at a constant rate of 72 mls/hour.
EXAMPLE ~
Hepatic insufficiency was induced in previously healthy Sprague-Dawley CRl:CD rats by portacaval anastomosis. An end-to side portacaval anastomosis (shunt) was induced by a nonsuture method using Teflon tubing. For three weeks following surgery, the rats were returned to stainless steel cages and allowed ~o consume laboratory chow, ad libitum. After that period in time, 24 animals were fasted overnight and hepatic function assessed by both static and dynamic indices. Results were compared to 20 similar animals that received only a sham operation.
In 12 portacaval shunted rats and 10 sham operated rats, indocyanine green clearance~ an index of hepatocyte function, was evaluated.
Fifteen minutes following intravenous injection of ~ndocyanin2 green, both sham operated and portacaval shunted rats were killed and results are summarized in Table 1.
lZ4Zg~
TABLE 1 Portocaval Shunt (PCS) Effects on Body ~leight, Liver Weight, Indocyanine Green Clearance and Serum Albumin Concentrations - -Indocyanine Body Welght (g) Liver Green Serum Albumin Before After Weight (g) Retention(%) (g/dl) SHAM 274+8 351+15 8.9~0.6 9.0+3.3 3.05~0.04 PCS 277~23 301+35 6.2+0.4* 18.3+4.7*2.68+0.16*
*p n.o5 Hepatic dysfunction was clearly evident. Liver weight in portacaval shunted rats was 42% less than in sham operated animals (p 0.05) and serum albumin concentration (a liver synthesized protein) was also significantly reduced (p 0.05).
As a dynamic assessment of hepatocyte function, indocyanine green retention was almost twice as great (p 0.05) in portacaval shunted rats indicating reduced clearance.
In addition to these assessments, hepatic reticuloendothelial system function was evaluated in 12 additional portacaval shunted rats and 10 sham operated rats.
The blood concentration of live Pseudomonas aeruginosa P4 in portacaval shunted rats following an intravenous challenge of 5X108 cfu of bacteria was about ten times greater (one log) than the sham operated group (Table 2) (p 0.05). Although the capacity to clear bacteria was reduced in portacaval shunted rats, the capacity of the spleens to sequester Pseudomonas was markedly increased, indicating a compensatory role by that organ.
~24zg7 TABLE 2 Effect of PCS on Host Nonspecific Immunity and Organ Reticuloendothelial System Function Blood Bacteremia (log conc.) Organ Sequestration i%) O' 30' 60' Liver Spleen SHAM 74.5+0.3 3.0+0.3 35+2 6+1 PCS 75.4+0.2* 4.2+0.2* 38+2 12+1 _ *p 0.05 Therefore, the portacaval shunt model in the rat produced a hepatic ~nsufficiency model which mimics in many ways the clinical conditions seen in human liver disease.
Twenty-eight male Sprague-Dawley CRl:CD rats underwent portacaval anastomosis and splenectomy and were returned to their metabolic units for 3 weeks. Following the recovery period, the rats were randomized to receive total parenteral nutrition for four days. All of the diets delivered 300 kcals/Kg BW/day and 12.5 g amino acid/day except for the dextrose only group t"D only") which received only 300 dextrose kcals/Kg BW/day. One group of animals received all of the nonprotein calories as dextrose ~AA+D) whereas the remaining two groups received half of their nonprotein calories as lipid. One of the lipid groups received its fat calories as a soybean (LCT) oil emulsion (AA+D~L) while the rema~ning lipid group received one-half o~ the fat calories as the 20~ MCT oil emulsion of example 7 and the other half as a 20% soybean oil emulsion (AA+D+PM).
~"~a,2~37~
TABLE 3 Protein Responses to Various TPN Regimens in Portocaval Shunted Rats.
Serum Albumin Fractional Synthetic Rate(%/d) N Balance (g/dl~ Albumin Muscle (mg/4 days) M+D+PM 3.2+0.3*85~14 5.7+2.2 61+14 AA+D~5T 3.0+0.5 84+15 6.1+1.2 20+35 AA+D 2.6+0.3 68+5 5.9+1.0 71+32 D only 2.4+0.5 20+8* 5.6+2.8 -150+10*
*p 0.05 vs M+D
Results summarized in Table 3 demonstrated that portacaval shunted rats given the 5~:50 physical mixture ~PM) of MCT
emulsion and soybean oil emulsion had the highest serum level of albumin (a hepatic secretory protein), and serum albumin levels were lowest in animals given only glucose. In addition, liver histologw (following hemotoxylin and eosin staining~ sho~ed marked infiltration of glycogen in the hepatocytes from rats infused with dextrose regimens (AA+D and D only). In contrast, in rats given all of their nonprotein calories as a soybean oil emulsion and glucose (Group AA+D+LCT) increased lipid sequestration in the Kupffer cells was observed. Rats given nonprotein calories as glucose and the physical mix of soybean and MCT oil emulsion (AA+D~PM) had normal hepatic physiology.
The improved liver morphology and albumin concentration in the rats given the 50:50 physical mix of soybean oil emulsion and MCT oil emulsion support the conclusion that MCTs as a component of total parenteral nutrition are an effective energy source during hepatic dysfunction.
~2~ 2~7~
The effect of MCT emulsions on reticuloendothelial system function was investigated in 2~ additional portacaval shunted rats that had also undergone splenectomy. Seven weeks following portacaval anastomosis and splenectomy, all animals received diets that delivered 200 kcals/Kg BW/day and 8.3 9 amino acid/Kg BW/day. Lipid was given at 50% of the total nonprotein calorie intake as either a 10% soybean oll emulsion (AA+D+LCT) or a 10%
MCT oil emulsion (AA+D+MCn. To assess reticuloendothelial system function following these courses of total parenteral nutrition, a body weight-related dose of E. coli was administered intravenously.
TABLE 4 Effect of MCT AND LCT on Reticuloendothelial System Function in PCS Ra~s N Blood Organ Balance Bacteria (log conc) Sequestration (%) (mg/5d) O' 30' 60' Liver Lung SHAM + AA~D+LCT 117+15 74.2+0.4* 3.4+0.236.4+1.212.5+1.2 PCS + M+D+LCT 101+38 75.5+0.3 4.8+0.242.1+2.315.5+2.0 PCS + AA+D+M~T 105+18 74.5+001* 3.9+0.2* 55.7+4.5* 8.4+0.7*
*p 0.05 vs PCS +AA+D+LCT
No differences in nitrogen balance were observed (Table 4).
However, decreased bacterial clearance and liver uptake of E.
coli indicakive of hepatic reticuloendolthelial system blockade were seen 1n portacaval shunted and splenectomized rats given lipid calories as a soybean oil emulsion. Such results suggest that administration of LCT oil emulsions without MCTs may have adverse effects during hepatic insufficiency. In contrast, intravenous MCT emulsions support nitrogen balance equally well 9~
and may better support hepatic reticuloendothelial system function in order to improve sequestration of organisms in the liver during bacteremia.
This contemplated example demonstrates the use of an MCT
emulsion in providing parenteral nutrition to a liver diseased patient.
A 47-year-old ~hite male (62 K~) is admitted to the hospital because of delirium and hematemesis. The patient had a 25 year history of alcohol abuse and on a previous admission had biopsy proven alcoholic cirrhosis. Gastroscopy had demonstrated the presence of extensive esophageal varices.
Laboratory analysis of the patient confirmed the clinical diagnosis of variceal bleeding secondary to decompensated alcoholic cirrhosis. Total bilirubin was 7 mg/dl (normal less than 1 mg/dl); serum glutamate-oxalo acetate transaminase was 80 U/L (normal less than 15 U/L). Serum glutamate pyruvate transaminase was 155 U/L (normal less than 15 U/L) and serum gamma glutaryl transaminase was 180 U/L (normal less than 30 U/L). Hemoglobin was 7.5 g/l (normal = 1~-16 9/1).
Serum alburnin concentration was 1.9 g/dl (normal greater than 3.5 g/dl) and total protein 4.4 g/dl (normal greater than 6 g/dl) reflecting visceral protein attrition. Abnormalities in the serum amino acid pattern were also evident with L-tyrosine being 274 nmols/ml (normal 50-100 nmols/ml) and L-phenylalanine being 332 nmols/ml (normal 50-100 nmols/ml). The serum aromatic to branched chain amino acid ratio was 2.7~ with normal being less than 0.80.
The patient's mental condition varied from Grade II to Grade III coma and the patient had severe asterixis. During the first two days of admission, 2 gms of neomycin, twice daily, and 20 mls of 10% lactolose three times daily, were administered. Due ~24Z9~
to acute alcohol wi~hdrawal, the patient's clinical course was complicated by the presence of alcohol-induced delirium tremens.
Because of the patient's reduced visceral protein status, nutritional support was recommended. Oral intake was not recommended because of the decreased mental status and presence of delirium tremens. Use of nasogastric feeding tube was also contraindicated because of esophageal varices. The physicians recommended total intravenous nutrition and a subclavlan catheter was inserted into the superior vena cava.
Nutritional support for the patient was set at a total calorie intake of 30 kcals/Kg BW/day and protein (as amino acid equivalents) at l.Og/Kg BW/day. The amino acid source was a standard amino acid mixture (Travasol amino acids) supplemented with the branched chain amino acids, leucine, isoleucine, and valine so that the total branched chain proportion was 50% of the total amino acids by weight.
The remaining 26 kcals/Kg BW/day were administered as 65%
hydrous glucose and 35% as a physical mixture of 20% MCT oil emulsion and 20% soybean oil emulsion. 75% of the lipid calories were given as the medium chain triglyceride oil emulsion and 25% of the lipid calories as a soybean oil emulsion. Actual daily intake of the hydrous glucose was 3.5 mg/Kg/min, of the soybean oil emulsion was 0.174 mg/Kg/min and of the MCT oil emulsion, 0.585 mg/Kg/min. Electrolytes, trace minerals, and vitamins were adjusted daily to meet the established requirements of the patient.
The entire formula was admfnistered in a course of therapy commencing with 1720 ml of fluid continuously over a 24 hour period at a rate of 72 mls/hr through the subclavian vein catheter. The patient's condition was considered to have improved after treatment with the regimen of this Example.
Claims (11)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A sterile composition comprising an emulsion of MCTs and LCTs in an aqueous solution containing at least one branched chain amino acid or branched chain amino acid keto analogue.
2. The composition of claim 1 further comprising a carbohydrate.
3. The composition of claim 1 wherein the solution contains a mixture of essential and nonessential amino acids.
4. The composition of claim 3 wherein the total mole percent of the amino acids serine, glycine, threonine, tryptophan, glutamine and histidine in the mixture is about from 8% to 16%.
5. The composition of claim 3 wherein the total mole percent of branched chain amino acids in the mixture is greater than about 35%.
6. The composition of claim 5 wherein the percent is about from 40% to 60%.
7. The composition of claim 1 wherein the branched chain amino acid analogue is .alpha.-ketoisovaleric acid, .alpha.-ketoisocaproic acid or .alpha.-keto- .beta.-methylvaleric acid.
8. The composition of claim 1 wherein the LCTs and MCTs are present in separate lipid particles.
9. The composition of claim 1 wherein each particle is a mixture of LCTs and MCTs.
10. The composition of claim 1 which is hermetically sealed in a container.
11. A sterile emulsion comprising, in relative weight proportion (a) MCTs, about from 2.5 to 187;
(b) branched chain amino acids, about from 12.25 to 105; and (c) LCTs, about from 7.8 to 187.
(b) branched chain amino acids, about from 12.25 to 105; and (c) LCTs, about from 7.8 to 187.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57102184A | 1984-01-16 | 1984-01-16 | |
US571,021 | 1984-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1242974A true CA1242974A (en) | 1988-10-11 |
Family
ID=24282010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000471737A Expired CA1242974A (en) | 1984-01-16 | 1985-01-09 | Parenteral nutrition with medium and long chain triglycerides |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0168425A4 (en) |
JP (1) | JPS61501558A (en) |
CA (1) | CA1242974A (en) |
WO (1) | WO1985003002A1 (en) |
ZA (1) | ZA85202B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4678807A (en) * | 1984-03-01 | 1987-07-07 | Baxter Travenol Laboratories, Inc. | Method for directed visceral metabolism of medium chain triglycerides |
SE8803141L (en) * | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | FOOD FOR FOOD AND ANIMALS |
SE8803142L (en) * | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | NEW ENERGY SUBSTRATE |
EP0537113A1 (en) * | 1991-10-10 | 1993-04-14 | SANDOZ NUTRITION Ltd. | Energy supplementary food |
JP2990686B2 (en) * | 1994-11-17 | 1999-12-13 | 田辺製薬株式会社 | Total infusion containing water-soluble vitamin B |
US6835408B2 (en) * | 1998-11-13 | 2004-12-28 | The Nisshin Oillio Group, Ltd. | Oil or fat composition |
EP2300020B1 (en) | 2008-07-07 | 2018-06-27 | Pentec Health, Inc. | Nutritive compositions and methods of using same |
US20140066439A1 (en) | 2010-11-10 | 2014-03-06 | Katholieke Universiteit Leuen, K.U.Leuven R&D | Osteoclast activity |
EP3664628A4 (en) * | 2017-08-10 | 2021-04-14 | The Children's Medical Center Corporation | Methods and compositions relating to emulsions comprising fish oil and/or omega-3 fatty acids |
WO2019125913A1 (en) * | 2017-12-20 | 2019-06-27 | Michael Guarnieri | Nutritional bolus for animals |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS537492B2 (en) * | 1973-02-12 | 1978-03-18 | ||
US4112123A (en) * | 1976-07-21 | 1978-09-05 | Beatrice Foods Co. | Nutritionally balanced single food composition and method of production |
US4296127A (en) * | 1979-04-18 | 1981-10-20 | The Johns Hopkins University | Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof |
JPS5681515A (en) * | 1979-12-07 | 1981-07-03 | Tanabe Seiyaku Co Ltd | Amino acid transfusion |
FR2490631A1 (en) * | 1980-09-24 | 1982-03-26 | Roussel Uclaf | NOVEL LIPID COMPOSITION FOR USE IN DIETETICS, REANIMATION AND THERAPEUTICS |
DE3131460A1 (en) * | 1981-08-08 | 1983-02-24 | B. Braun Melsungen Ag, 3508 Melsungen | FAT EMULSION FOR PARENTERAL NUTRITION |
JPS58126767A (en) * | 1982-01-22 | 1983-07-28 | Ajinomoto Co Inc | Elemental diet for hepatopathic patient |
DE3368377D1 (en) * | 1982-04-16 | 1987-01-29 | Nestle Sa | Lipid composition for oral, enteral or parenteral feeding |
-
1984
- 1984-12-18 JP JP60500075A patent/JPS61501558A/en active Pending
- 1984-12-18 EP EP19850900428 patent/EP0168425A4/en not_active Ceased
- 1984-12-18 WO PCT/US1984/002073 patent/WO1985003002A1/en not_active Application Discontinuation
-
1985
- 1985-01-09 ZA ZA85202A patent/ZA85202B/en unknown
- 1985-01-09 CA CA000471737A patent/CA1242974A/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
EP0168425A4 (en) | 1989-03-09 |
ZA85202B (en) | 1985-09-25 |
JPS61501558A (en) | 1986-07-31 |
EP0168425A1 (en) | 1986-01-22 |
WO1985003002A1 (en) | 1985-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4703062A (en) | Parenteral nutrition with medium and long chain triglycerides | |
JP6682596B2 (en) | Self-emulsifying composition of ω3 fatty acid | |
KR101503970B1 (en) | Omega-3 enriched fish oil-in-water parenteral nutrition emulsions | |
EP1973552B1 (en) | Parenteral nutrition composition containing iron | |
CA2069413A1 (en) | Method for reducing blood cholesterol using arginine | |
CA1242974A (en) | Parenteral nutrition with medium and long chain triglycerides | |
JP2509810B2 (en) | Parenteral lipid emulsion for visceral-directed metabolism of medium-chain triglycerides | |
Mullen et al. | Role of nutrition in hepatic encephalopathy | |
TWI749451B (en) | Pharmaceutical composition comprising omega fatty acids, and infusion preparation comprising the same | |
JP3908513B2 (en) | Liver function improving agent | |
JP4394174B2 (en) | Inflammatory bowel disease treatment | |
AU580278B2 (en) | Treating liver diseases in patients by administering compositions of medium and long chain triglycerides | |
US5567736A (en) | Use of a choline salt to inhibit fatty liver in patients receiving total parenteral nutrition | |
Tsukamoto et al. | Hepatic origin of triglycerides in fatty livers produced by the continuous intragastric infusion of an ethanol diet | |
JPH0558878A (en) | Fat emulsion | |
JP2009544702A (en) | Omega-3 fatty acids for the treatment of resistant hypertension | |
CN116407502A (en) | Oral microemulsion with high EPA content and preparation method and application thereof | |
Simoens et al. | Tissue fatty acid (FA) pattern during fish oil supplemented total parenteral nutrition (TPN) in dogs | |
Connolly et al. | Infusion of high doses of LCT-and structured triglyceride-based fat emulsions does not affect the reticuloendothelial system (RES) of the rat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |